Proposed Budget Has Extra Funds for FDA Teen Smoking Effort

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 3
Volume 7
Issue 3

WASHINGTON--In his budget proposal, President Clinton has asked Congress to appropriate an additional $100 million for the FDA’s youth-tobacco prevention program. If approved, the increase would provide the program $134 million in fiscal year 1999.

WASHINGTON--In his budget proposal, President Clinton has asked Congress to appropriate an additional $100 million for the FDA’s youth-tobacco prevention program. If approved, the increase would provide the program $134 million in fiscal year 1999.

Overall, the President proposed $1.264 billion for the FDA, up from $1.077 billion currently. Of this amount, $294.1 million would come from user fees paid by groups regulated by the agency, including pharmaceutical companies.

The FDA’s antitobacco effort, a collaborative program with state and local authorities, seeks to reduce the access of underage users to tobacco products and cut tobacco use by children by 50% within 7 years. The proposal allocates $35 million for compliance outreach, $75 million for enforcement and evaluation, and $24 million for product regulation.

Related Videos
Cretostimogene grenadenorepvec’s efficacy compares favorably with the current nonsurgical standards of care in high-risk, Bacillus Calmette Guerin–unresponsive non-muscle invasive bladder cancer.
Artificial intelligence models may be “seamlessly incorporated” into clinical workflow in the management of prostate cancer, says Eric Li, MD.
Panelists smiling at camera on a blue background.
Panelists smiling at camera on a blue background.
Robust genetic testing guidelines in the prostate cancer space must be supported by strong clinical research before they can be properly implemented, says William J. Catalona, MD.
Treatment with tisotumab vedotin may be a standard of care in second- or third-line recurrent or metastatic cervical cancer, says Brian Slomovitz, MD, MS, FACOG.
A panel of 4 experts on multiple myeloma seated at a long table
A panel of 4 experts on multiple myeloma seated at a long table
Teresa Macarulla, MD, PhD, and Cindy Neuzillet, MD, PhD, experts on NRG1 fusion-positive malignancies
Related Content